Business
-
Minish Holds First Seminar in Japan with Great Success - Over 100 Dentists in AttendanceDetails
"Impressed by Extensive Full-Mouth Rehabilitation Cases","Anti-Aging Effects Highly Praised"
-
Reolink Makes Wireless Security Camera Systems Accessible to All HomesDetails
LOS ANGELES,Feb. 17,2025-- Every homeowner deserves peace of mind when it comes to home security. Reolink,an innovative leader in intelligent visual technology for the home,brings the Wireless Securi
-
Vantage Markets Recognized at the Global Brands Magazine Awards 2025Details
PORT VILA,Vanuatu,Feb. 17,2025-- Vantage Markets is honored to announce its recognition at the Global Brands Magazine (GBM) Awards 2025,where it has beenacknowledged for – "Best CFD Broker,APAC
-
Duke and Duke-NUS forge new frontiers in climate health research with S$1million fundingDetails
The two institutions awarded more than S$1 million to accelerate five promising areas of research collaboration
-
Thousand-year-old temple fair held in Central China's HenanDetails
XUN COUNTY,China,Feb. 14,2025-- On February 6,2025,the ninth day of the first lunar month,the 17th Central Plains (Hebi) Folk Culture Festival ushered in the Dapishan Temple Fair. The event was a vibr
-
Zeekr Group Announces the Closing of Strategic Integrated TransactionsDetails
HANGZHOU,China,Feb. 14,2025-- ZEEKR Intelligent Technology Holding Limited ("Zeekr Group" or the "Company") (NYSE: ZK),the world\'s leading premium new energy vehicle group,today a
-
A Global Leader! Huawei Cloud Stack Ranks No. 1 in Strategy and Execution of CloudOps WorldwideDetails
SHENZHEN,China,Feb. 14,2025-- Omdia released the Omdia Universe: CloudOps,2025 report recently. In the report,Huawei was ranked No. 1 globally in CloudOps in terms of strategy and execution,and No. 2
-
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003Details
SUZHOU,China,Feb. 13,2025-- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 bi
-
DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic DevelopmentDetails
SEOUL,South Korea,Feb. 13,2025-- DAAN Biotherapeutics,a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies,has signed an exclusive licensing agreement w
-
Study Results Abstracts From Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) At 2025 ASCO Genitourinary Cancers SymposiumDetails
CHENGDU,China,Feb. 13,2025-- At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2025,to be held in San Francisco,USA,from Feb. 13-15,2025,Sichuan Kelun-Biotech Bi